207 related articles for article (PubMed ID: 24149835)
1. Topics in lipoprotein glomerulopathy: an overview.
Saito T; Matsunaga A; Ito K; Nakashima H
Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
[TBL] [Abstract][Full Text] [Related]
2. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E-related glomerular disorders.
Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
[TBL] [Abstract][Full Text] [Related]
4. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein glomerulopathy in China.
Chen Y
Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
Saito T; Oikawa S; Sato H; Sato T; Ito S; Sasaki J
Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734
[TBL] [Abstract][Full Text] [Related]
7. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis.
Saito T; Matsunaga A
Kidney Int; 2014 Feb; 85(2):243-5. PubMed ID: 24487366
[TBL] [Abstract][Full Text] [Related]
9. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
Toyota K; Hashimoto T; Ogino D; Matsunaga A; Ito M; Masakane I; Degawa N; Sato H; Shirai S; Umetsu K; Tamiya G; Saito T; Hayasaka K
J Hum Genet; 2013 May; 58(5):254-8. PubMed ID: 23407349
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
Kato J; Okonogi H; Kanzaki G; Katsumata H; Nakada Y; Sagasaki M; Komine K; Ito K; Saito T; Matsunaga A; Tokutou K; Honda K; Tsuboi N; Yokoo T
BMC Nephrol; 2024 May; 25(1):171. PubMed ID: 38769490
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T
Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
[TBL] [Abstract][Full Text] [Related]
12. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Ieiri N; Hotta O; Taguma Y
Am J Kidney Dis; 2003 Jan; 41(1):244-9. PubMed ID: 12500244
[TBL] [Abstract][Full Text] [Related]
13. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
Saito T; Matsunaga A; Oikawa S
Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
[TBL] [Abstract][Full Text] [Related]
14. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Hu Z; Huang S; Wu Y; Liu Y; Liu X; Su D; Tao Y; Fu P; Zhang X; Peng Z; Zhang S; Yang Y
Kidney Int; 2014 Feb; 85(2):416-24. PubMed ID: 24025644
[TBL] [Abstract][Full Text] [Related]
15. Significance of a novel apolipoprotein E variant, ApoE Osaka/Kurashiki, in lipoprotein glomerulopathy.
Saito T; Matsunaga A
J Atheroscler Thromb; 2011; 18(6):542-3. PubMed ID: 21670560
[No Abstract] [Full Text] [Related]
16. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.
Bomback AS; Song H; D'Agati VD; Cohen SD; Neal A; Appel GB; Rovin BH
Nephrol Dial Transplant; 2010 Oct; 25(10):3442-6. PubMed ID: 20624773
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC
Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
[TBL] [Abstract][Full Text] [Related]
18. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
[TBL] [Abstract][Full Text] [Related]
19. A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.
Stratikos E; Chroni A
Clin Exp Nephrol; 2014 Apr; 18(2):225-9. PubMed ID: 24149834
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.
Wu H; Yang J; Liu YQ; Lei S; Yang M; Yang Z; Yang Y; Hu Z
J Transl Med; 2021 Mar; 19(1):97. PubMed ID: 33663537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
